Michele Yang

OverviewAI-generated summary

Michele Yang's research focuses on the study of rare genetic disorders, particularly Duchenne muscular dystrophy (DMD) and Bardet-Biedl syndrome (BBS). Her work investigates the efficacy and safety of therapeutic interventions for these conditions, as demonstrated by her publication on the 48-week efficacy and safety of Vamorolone in boys with DMD. Yang also explores the underlying mechanisms of neurodevelopmental disorders, including research on loss-of-function mutations in GEMIN5. Her recent work includes the identification of circulating protein biomarkers in glucocorticoid-naive DMD patients and consensus recommendations for gene therapy delivery and monitoring in DMD patients.

Yang's research interests extend to various aspects of pediatric and rare disease care. She has examined the risk of emergency room or inpatient admission following neurology telemedicine visits during the COVID-19 pandemic. Additionally, she has contributed to the psychometric evaluation of questionnaires designed to assess hyperphagia in patients with BBS. Her scholarship metrics include an h-index of 26 and over 2,700 total citations, reflecting a significant body of published work. Yang leads a research group and collaborates with other researchers, including Aravindhan Veerapandiyan at the University of Arkansas for Medical Sciences.

Metrics

• h-index: 26
• Publications: 74
• Citations: 2,732